Table 7. Oncogenomics-based myeloma... | American Society of Hematology

Table 7.

Oncogenomics-based myeloma classification system.

Study	Type of genomic study	No. patients	Outcome measure	Applications/limitations
* KIF14, SLC19A, CKS1B, YWHAZ, MPHOSPH1, TMPO, NADK, LARS2, TBRG4, AIM2, ASPM, AHCYL1, CTBS, MCLC, LTBP1, 242488_at, 1557277_a_at
† CNDP2, STMN1, AFG3L2, STK38, PARP1, CPSF6, LOC151162, TOX2, FRY, FLJ21438, MGST1, ALDH2, CTSF, ATF4, FAM49A
Bergsagel et al¹⁶	Cytogenetics/FISH and expression profile	—	8 translocation/cyclin D (TC) groups	Combinations of methods being used.   Difficult to apply. Clinical relevance unclear.
Shaughnessy et al²⁹	Expression profile – 17-gene model*	532	High- and low-risk groups	Applicable to general population but requires validation.
Decaux et al³⁰	Expression profile – 15-gene model†	182	High and low risk groups	Applicable to general population but requires validation.
Carrasco et al³¹	aCGH profile	67	Four groups based on amplifications and deletions	Difficult to apply in general population yet

Study	Type of genomic study	No. patients	Outcome measure	Applications/limitations
* KIF14, SLC19A, CKS1B, YWHAZ, MPHOSPH1, TMPO, NADK, LARS2, TBRG4, AIM2, ASPM, AHCYL1, CTBS, MCLC, LTBP1, 242488_at, 1557277_a_at
† CNDP2, STMN1, AFG3L2, STK38, PARP1, CPSF6, LOC151162, TOX2, FRY, FLJ21438, MGST1, ALDH2, CTSF, ATF4, FAM49A
Bergsagel et al¹⁶	Cytogenetics/FISH and expression profile	—	8 translocation/cyclin D (TC) groups	Combinations of methods being used.   Difficult to apply. Clinical relevance unclear.
Shaughnessy et al²⁹	Expression profile – 17-gene model*	532	High- and low-risk groups	Applicable to general population but requires validation.
Decaux et al³⁰	Expression profile – 15-gene model†	182	High and low risk groups	Applicable to general population but requires validation.
Carrasco et al³¹	aCGH profile	67	Four groups based on amplifications and deletions	Difficult to apply in general population yet